04:24 PM EDT, 10/31/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) reported Q3 non-GAAP earnings late Thursday of $1.27 per diluted share, up from $0.75 a year earlier.

Analysts polled by Capital IQ expected $1.00.

Revenue for the quarter ended Sept. 30 was $290.1 million, up from $216 million a year earlier.

Analysts surveyed by Capital IQ expected $252.2 million.

The company said it now expects 2024 non-GAAP diluted EPS between $4.00 and $4.20 and revenue between $970 million and $1.02 billion.

The previous guidance was non-GAAP diluted EPS between $3.65 and $4.05 and revenue between $935 million and $1.02 billion.

Analysts polled by Capital IQ expect $3.96 and $983.9 million.